Consequently,
Anti -choolésterol: sanofi suspends his:
(AFP / Guillaume Souvant)
The pharmaceutical giant Sanofi announced on Friday at AFP suspending its request for the reimbursement of its anti-cholesterol praluent drug, saying working to “a lasting solution” with the health authorities to guarantee access to this essential treatment against cardiovascular risk. In addition,
On June 26. In addition, the group had asked for the reimbursement of this injectable antibody against hypercholesterolemia, believing that it was “no longer economically viable” to continue to respond to the explosion of demand. However,
“Sanofi decided to suspend his request for a reimbursement,” a spokesperson said on Friday. Therefore, The group says it is working “with the authorities in the development in the coming weeks of anti -choolésterol: sanofi suspends his a collective. Therefore, sustainable solution which would guarantee access to Praluent in the best conditions, today and tomorrow”.
The number of patients treated with praluent (alirocumab) has not ceased to increase since 2020. even doubling between 2023 and 2024 due to the expansion of situations where the drug can be prescribed, but “without the conditions for providing treatment being adapted by the authorities”, underlines Sanofi.
The prospect of possible reimbursement arouses the concern. the misunderstanding of specialists and patients at high neuro-cardiovascular risk who hope for an agreement between the State and the laboratory.
Cardiovascular diseases constitute “the second cause of mortality in France after cancers. the first in women,” said Franck Boccara, head of the cardiology department at the Saint-Antoine-Tenon CHU during a webinar on Thursday to take stock of the situation.
“There is a risk of seeing an upsurge in anti -choolésterol: sanofi suspends his heart problems: infarction. angina of chest or stroke” in the event of a break in access, according to Sophie Beliard, nutrition professor at the AP-HM in Marseille.
The president of the National Association of Family Hypercholesterolemies and Lipoproteins (Anhet.F), Lionel Ribes, said that this situation would generate “extreme concern” and “an anxiety of recurrence” in high -risk patients.
In the first quarter, praluent sales reached 130 million euros, up 6.6%, reflecting an increase in sales in Europe.
Sanofi recalls having invested more than 20 million euros in France to strengthen its industrial capacities. in particular on its Vitry-sur-Seine site, in the Paris region, dedicated to monoclonal antibodies, which will ensure, this year, 80% of the global production of the active substance of Praluent.
In 2019, the group stopped research on the very competitive sector of diabetes and cardiovascular.
Anti -choolésterol: sanofi anti -choolésterol: sanofi suspends his suspends his
Further reading: The Domaine Tardieu Ferrand En Fête – How old are your organs really? – green light to reimbursement, but still not in the vaccination calendar – Valneva: EMA rises the suspension of the use of the IXCHIQ vaccine for the elderly – Parkinson: the laterality of motor symptoms at the start of the disease influences its evolution | The doctor’s daily life | Medical news.
 The pharmaceutical giant Sanofi…){kind=link}